公开(公告)号：US20060198842A1

公开(公告)日：2006-09-07

申请号：US11412025

申请日：2006-04-26

Applicant: Robert Isfort ,  Russell Sheldon

Inventor： Robert Isfort ,  Russell Sheldon

IPC: A61K39/395 ,  A61K38/17

CPC classification number: A61K49/0004 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/21 ,  G01N33/566 ,  G01N2333/726 ,  G01N2500/10

Abstract: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.

Abstract translation: 公开了用于鉴定结合或激活促肾上腺皮质激素释放因子2受体（CRF 2 R R）并调节或潜在地调节骨骼肌质量或体内功能的化合物的筛选方法。 还公开了用于鉴定延长或增加CRF2RS信号或CRF2R信号转导途径的活化的化合物的筛选方法，增加CRF 2 R 2信号转导通路 提供R或增加CRF表达。 包含CRF 2 R激动剂的药物组合物，CRF 2 R R的抗体以及用于增加骨骼肌质量或功能或使用CRF 2治疗骨骼肌萎缩的方法 描述了作为干预目的的R / R和治疗肌营养不良症的方法。

公开(公告)号：US20060183735A1

公开(公告)日：2006-08-17

申请号：US11345948

申请日：2006-02-02

Applicant: Robert Isfort ,  Russell Sheldon

Inventor： Robert Isfort ,  Russell Sheldon

IPC: A61K31/55 ,  C12Q1/00

CPC classification number: G01N33/9413 ,  A61K31/55 ,  G01N33/566 ,  G01N2500/04 ,  G01N2800/2878

Abstract: Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine receptors or of D1 or D5 dopamine receptor signal transduction pathways and increase D1 or D5 dopamine receptor expression. Pharmaceutical compositions comprising D1 or D5 dopamine receptor agonists, antibodies to D1 or D5 dopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using D1 or D5 dopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.

Abstract translation: 用于鉴定结合或活化（D 1 N或D 5多巴胺受体单独或组合）的化合物的筛选方法或调节或潜在地调节骨骼肌质量或体内功能。 还公开了用于鉴定延长或增加D 1 N或D 5 N多巴胺受体或D 1 N或D 3多巴胺受体活化的化合物的筛选方法， 多巴胺受体信号转导途径，并增加D 1 N或D 5多巴胺受体表达。 包含D 1或D 5 N多巴胺受体激动剂的药物组合物，D 1或D 5多巴胺受体的抗体和 用于增加骨骼肌质量或功能的方法或使用D 1或D 5多巴胺受体作为干预目标和用于治疗肌营养不良症的方法来治疗骨骼肌萎缩的方法 被描述。

公开(公告)号：US20060025339A1

公开(公告)日：2006-02-02

申请号：US11121612

申请日：2005-05-04

Applicant: Robert Isfort ,  Wieslaw Mazur

Inventor： Robert Isfort ,  Wieslaw Mazur

IPC: A61K38/22

CPC classification number: C07K14/57509 ,  A61K38/00

Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

公开(公告)号：US20070015214A1

公开(公告)日：2007-01-18

申请号：US11487848

申请日：2006-07-17

Applicant: Robert Isfort ,  Russell Sheldon

Inventor： Robert Isfort ,  Russell Sheldon

IPC: A61K31/557 ,  G01N33/53

CPC classification number: G01N33/92 ,  G01N2500/00 ,  G01N2800/10

Abstract: Methods for identifying compounds that bind to or activate prostanoid IP receptors and potentially regulate skeletal muscle mass or function are disclosed. Pharmaceutical compositions comprising IP receptor agonists and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using IP receptor as the target for intervention and methods for treatment of muscular dystrophies are described.

Abstract translation: 公开了鉴定结合或激活前列腺素类IP受体并潜在调节骨骼肌质量或功能的化合物的方法。 描述了包含IP受体激动剂的药物组合物和用于增加骨骼肌质量或功能的方法或使用IP受体作为干预的靶标和用于治疗肌营养不良症的方法来治疗骨骼肌萎缩的方法。

公开(公告)号：US20080004435A1

公开(公告)日：2008-01-03

申请号：US11701912

申请日：2007-02-02

Applicant: Robert Isfort ,  Wieslaw Mazur

Inventor： Robert Isfort ,  Wieslaw Mazur

IPC: C07H21/00

CPC classification number: C07K14/57509 ,  A61K38/00

Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

Abstract translation: 分离的促肾上腺皮质激素释放因子衍生物和编码它们的核酸对于治疗促肾上腺皮质激素释放因子2受体调节障碍如肌营养不良是有效的。